When to Switch GLP-1 Medications: A Clinical Decision Framework
Switching between GLP-1 medications — or between semaglutide and tirzepatide specifically — is a real clinical decision with a logic behind it, not an arbitrary preference. Here's the decision framework.
Common clinical reasons to consider switching
- Inadequate response at maximum tolerated dose of the current medication after an appropriate trial period
- Intolerable side effects that don't improve with dose adjustment or supportive management
- Access or cost changes making the current medication no longer practical, even if it's working well
What switching between semaglutide and tirzepatide involves
No washout period is generally required — treatment with the new medication typically begins on the next scheduled dose. However, there's no direct 1:1 dose conversion between the two molecules; most protocols restart titration at the new medication's induction dose rather than assuming equivalence, since cross-tolerance isn't guaranteed.
MadeMed $167–$229
Both semaglutide and tirzepatide options, useful if a switch is clinically indicated.
Ageless Custom
A provider that can evaluate whether a medication switch is clinically appropriate for your situation.
Visit Ageless →Paid linkWhat patients should know
A switch usually means restarting titration, not picking up where you left off on your prior medication — that's a normal part of the process, not a sign something went wrong with the switch itself.